Kinetics of eotaxin expression and its relationship to eosinophil accumulation and activation in bronchial biopsies and bronchoalveolar lavage (BAL) of asthmatic patients after allergen inhalation

We investigated the kinetics of allergen‐induced eotaxin expression and its relationship to eosinophil accumulation and activation in the airways of patients with allergic asthma. Twenty‐four patients with allergic asthma and late asthmatic responses to allergen inhalation were randomly allocated into three groups of eight patients each, who received bronchoscopy with bronchial biopsies and BAL at 2, 4 and 24 h, respectively, after the inhalation of the diluent and the allergen. The expression of eotaxin mRNA and protein and eotaxin release were evaluated by in situ hybridization, immunohistochemistry, immunocytochemistry, and radioimmunoassay. Increased transcription from the eotaxin gene preceded the appearance of the late asthmatic response and the influx of activated eosinophils in bronchial tissue and BAL fluid (BALF). This was followed by increased cell expression of eotaxin protein (P < 0.001) and increased eotaxin release (P < 0.001), which correlated with the numbers of total and activated eosinophils and the level of airflow obstruction at 4 h after allergen exposure (P < 0.05 for all correlations). At 24 h after allergen inhalation, enhanced eotaxin expression declined without a similar reduction in the numbers of eosinophils in bronchial biopsies and when there was a further increase in the number of these cells in BALF (P < 0.05). These results indicate that eotaxin contributes to the early phase of allergen‐induced recruitment of activated eosinophils into the airways of patients with allergic asthma and that other factors are implicated in the persistence of eosinophil infiltration.

[1]  C. Mackay,et al.  Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co‐localization of eotaxin mRNA to bronchial epithelial and endothelial cells , 1997, European journal of immunology.

[2]  S. Holgate,et al.  Release of RANTES, MIP-1 alpha, and MCP-1 into asthmatic airways following endobronchial allergen challenge. , 1997, American journal of respiratory and critical care medicine.

[3]  Q. Hamid,et al.  Increased expression of eotaxin in bronchoalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of inflammation. , 1997, Journal of immunology.

[4]  T. Williams,et al.  Eotaxin protein and gene expression in guinea-pig lungs: constitutive expression and upregulation after allergen challenge. , 1997, The European respiratory journal.

[5]  S. Rankin,et al.  Kinetics of Eotaxin Generation and Its Relationship to Eosinophil Accumulation in Allergic Airways Disease: Analysis in a Guinea Pig Model In Vivo , 1997, The Journal of experimental medicine.

[6]  M. Stacey,et al.  Eotaxin expression and eosinophilic inflammation in asthma. , 1997, Biochemical and biophysical research communications.

[7]  S. Peters,et al.  Kinetics of the development and recovery of the lung from IgE-mediated inflammation: dissociation of pulmonary eosinophilia, lung injury, and eosinophil-active cytokines. , 1997, American journal of respiratory and critical care medicine.

[8]  H. Kita,et al.  Eosinophil recruitment is associated with IL-5, but not with RANTES, twenty-four hours after allergen challenge. , 1996, The Journal of allergy and clinical immunology.

[9]  P. Leder,et al.  Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia , 1996, Nature Medicine.

[10]  W Newman,et al.  Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. , 1996, The Journal of clinical investigation.

[11]  N. Copeland,et al.  Mouse Eotaxin expression parallels eosinophil accumulation during lung allergic inflammation but it is not restricted to a Th2-type response. , 1996, Immunity.

[12]  A. Bellini,et al.  Bronchial epithelial cells of atopic patients with asthma lack the ability to inactivate allergens. , 1995, Biochemical and biophysical research communications.

[13]  M. Jordana,et al.  Effects of allergen challenge on eosinophils, eosinophil cationic protein, and granulocyte-macrophage colony-stimulating factor in mild asthma. , 1995, American journal of respiratory and critical care medicine.

[14]  P. Leder,et al.  Constitutive and allergen-induced expression of eotaxin mRNA in the guinea pig lung , 1995, The Journal of experimental medicine.

[15]  A. Wardlaw,et al.  Eosinophils: biology and role in disease. , 1995, Advances in immunology.

[16]  M. Seminario,et al.  The role of eosinophils in the pathogenesis of asthma. , 1994, Current opinion in immunology.

[17]  I. Adcock,et al.  Eotaxin: cloning of an eosinophil chemoattractant cytokine and increased mRNA expression in allergen-challenged guinea-pig lungs. , 1994, Biochemical and biophysical research communications.

[18]  A. Bellini,et al.  Detection of cytokines and their cell sources in bronchial biopsy specimens from asthmatic patients. Relationship to atopic status, symptoms, and level of airway hyperresponsiveness. , 1994, Chest.

[19]  J. Hsuan,et al.  Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation , 1994, The Journal of experimental medicine.

[20]  T. Williams,et al.  The chemokine, eotaxin, activates guinea-pig eosinophils in vitro and causes their accumulation into the lung in vivo. , 1993, Biochemical and biophysical research communications.

[21]  S. Peters,et al.  Eosinophil survival activity identified as interleukin-5 is associated with eosinophil recruitment and degranulation and lung injury twenty-four hours after segmental antigen lung challenge. , 1993, The Journal of allergy and clinical immunology.

[22]  W. Busse,et al.  Mechanism of airway inflammation in asthma. , 1993, The American review of respiratory disease.

[23]  H. Kauffman,et al.  Dynamics of eosinophil infiltration in the bronchial mucosa before and after the late asthmatic reaction. , 1993, The European respiratory journal.

[24]  P. Weller,et al.  Mechanisms of eosinophil recruitment. , 1993, American journal of respiratory cell and molecular biology.

[25]  W. Busse,et al.  IL-5 is the predominant eosinophil-active cytokine in the antigen-induced pulmonary late-phase reaction. , 1993, The American review of respiratory disease.

[26]  K. Chung.  The eosinophil in airway inflammation: potential role and pharmacologic modulation , 1993 .

[27]  S. Durham,et al.  Increases in activated T lymphocytes, eosinophils, and cytokine mRNA expression for interleukin-5 and granulocyte/macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics. , 1993, American journal of respiratory cell and molecular biology.

[28]  S. Durham,et al.  Application of monoclonal antibodies against major basic protein (BMK‐13) and eosinophil cationic protein (EG1 and EG2) for quantifying eosinophils in bronchial biopsies from atopic asthma , 1992, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[29]  S. Mattoli,et al.  A bronchial epithelial cell-derived factor in asthma that promotes eosinophil activation and survival as GM-CSF. , 1991, The American journal of physiology.

[30]  L. Allegra,et al.  Cellular and biochemical characteristics of bronchoalveolar lavage fluid in symptomatic nonallergic asthma. , 1991, The Journal of allergy and clinical immunology.

[31]  Lung,et al.  National asthma education program expert panel report. Guidelines for the diagnosis and management of asthma , 1991 .

[32]  Guidelines for the diagnosis and management of asthma. National Heart, Lung, and Blood Institute. National Asthma Education Program. Expert Panel Report. , 1991, The Journal of allergy and clinical immunology.

[33]  E. Coligan.  Current protocols in immunology , 1991 .

[34]  J. Bousquet,et al.  Eosinophilic inflammation in asthma. , 1990, The New England journal of medicine.

[35]  L. Allegra,et al.  Specific binding of endothelin on human bronchial smooth muscle cells in culture and secretion of endothelin-like material from bronchial epithelial cells. , 1990, American journal of respiratory cell and molecular biology.

[36]  J. Gamble,et al.  Recombinant human interleukin 5 is a selective activator of human eosinophil function , 1988, The Journal of experimental medicine.

[37]  D. Cockcroft,et al.  Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine. , 2015, The American review of respiratory disease.

[38]  P. O'Byrne,et al.  Late asthmatic responses. , 1987, The American review of respiratory disease.

[39]  H. Sluiter,et al.  Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. , 1985, The American review of respiratory disease.

[40]  I. Olsson,et al.  Monoclonal antibodies distinguish between storage and secreted forms of eosinophil cationic protein , 1984, Nature.

[41]  M. Kaliner,et al.  Late Phase Allergic Reactions , 1983, International journal of dermatology.

[42]  B. M. Brown,et al.  Practical Non-Parametric Statistics. , 1981 .